| Literature DB >> 33368923 |
Laura Cutando1, Emma Puighermanal1,2, Laia Castell1, Pauline Tarot1, Federica Bertaso1, Patricia Bonnavion3, Alban de Kerchove d'Exaerde3, Elsa Isingrini4,5, Micaela Galante6, Glenn Dallerac6, Vincent Pascoli7, Christian Lüscher7, Bruno Giros4,5, Emmanuel Valjent1.
Abstract
Prescription stimulants, such as d-amphetamine or methylphenidate are used to treat suffering from attention-deficit hyperactivity disorder (ADHD). They potently release dopamine (DA) and norepinephrine (NE) and cause phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluA1 in the striatum. Whether other brain regions are also affected remains elusive. Here, we demonstrate that d-amphetamine and methylphenidate increase phosphorylation at Ser845 (pS845-GluA1) in the membrane fraction of mouse cerebellum homogenate. We identify Bergmann glial cells as the source of pS845-GluA1 and demonstrate a requirement for intact NE release. Consequently, d-amphetamine-induced pS845-GluA1 was prevented by β1-adenoreceptor antagonist, whereas the blockade of DA D1 receptor had no effect. Together, these results indicate that NE regulates GluA1 phosphorylation in Bergmann glial cells in response to prescription stimulants.Entities:
Keywords: Bergmann glial cells; GluA1; cerebellar cortex; monoaminergic system; prescription stimulants
Mesh:
Substances:
Year: 2020 PMID: 33368923 DOI: 10.1111/adb.12995
Source DB: PubMed Journal: Addict Biol ISSN: 1355-6215 Impact factor: 4.280